Tritax Big Box expands portfolio in 2018 – Tritax Big Box has released its 2018 results today. Some of the highlights are: dividends declared in 2018 totalled 6.70p per share, meeting its target. The earnings per share increased by 8.0% to 6.88p per share in 2018. EPRA NAV per share increased 7.4% resulting in a […]
Foresight Solar 2018 results published: Things looking up Foresight Solar has announced its results for the 2018 year, and things are looking up. NAV has increased to £610.3m from £481.3m in the previous year, and NAV per share increased to 111.2p from 107.0p (a 4.9% increase in total return terms). This was essentially due to […]
Apax Global Alpha has strong results despite market negativity – Apax Global Alpha has announced its 2018 results today. NAV return in total terms was +7.1% or +5.4% in constant currency (which adjusts figures to remove the impact of foreign exchange rates). This demonstrates a solid performance of the private equity portfolio and a strong contribution […]
Biopharma Credit increases diversity of portfolio – BioPharma Credit has published their annual report for the 2018 year. They have invested in three new companies totalling $494 million which greatly increased the scale and diversity of their portfolio. They have also deployed a further $164 million to support previous investment agreements. Tesaro Inc. was acquired […]
RIT Capital Partners outperforms equity markets in 2018 results – RIT Capital Partners has released its results for the 2018 year. In summary, the NAV per share returned 0.8% in total return terms, which outperformed equity markets. Their investments beat RIT’s equity index benchmark (the MSCI All Country World Index in sterling and local currencies) by […]
Syncona’s Nightstar Therapeutics to be acquired for $877m – Syncona Limited founded Nightstar Therapeutics in 2013, with an original investment of £56.4m. Syncona’s holding of Nightstar at the time of sale was £254.6m, a £135.4m uplift previous valuation. This results in a 4.5x multiple on Syncona’s original investment and an internal rate of return (IRR) […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated